WHO, Nigerian Academy of Pharmacy Urge Nigeria to Achieve 70% Local Medicine Production Target by 2030.
The World Health Organisation (WHO) and the Nigerian Academy of Pharmacy have called on the Federal Government to accelerate local pharmaceutical manufacturing, strengthen drug regulation and increase investment in research and innovation, warning that Nigeria’s heavy reliance on imported medicines poses risks to national health security.
The call was made on Tuesday, November 17, 2026, during the Nigerian Academy of Pharmacy’s 2026 Annual General Meeting and Investiture of New Fellows, held under the theme, “Pharmacy for National Health Security: Advancing Innovation, Medicine Sovereignty and Sustainable Healthcare.”
In a keynote address delivered on behalf of WHO Country Representative in Nigeria, Dr Pavel Ursu, by Dr Akinola Fatiregun, the organisation emphasised the need for Nigeria to develop a resilient pharmaceutical industry capable of meeting more of its domestic medicine requirements.
According to the WHO representative, the Presidential Initiative for Unlocking the Healthcare Value Chain has established a target of achieving 70 per cent local pharmaceutical production by 2030.
He explained that strengthening domestic manufacturing would reduce the country’s exposure to disruptions in international supply chains, improve access to essential medicines and enhance Nigeria’s ability to respond to public health emergencies.
The WHO also identified six areas for stronger collaboration with the Academy, including policy development, implementation research, regulatory science, workforce development, pharmacists’ participation in health emergencies, and efforts to address antimicrobial resistance and improve pharmacovigilance.
The organisation further highlighted the importance of strengthening quality standards, supporting domestic production of active pharmaceutical ingredients (APIs), and exploring opportunities under the African Continental Free Trade Area (AfCFTA) to expand access to locally manufactured medicines across the continent.
Speaking at the event, President of the Nigerian Academy of Pharmacy, Professor Lere Baale, urged newly inducted fellows to use their professional expertise to advance pharmaceutical innovation, mentorship and national development.
Baale maintained that Nigeria possesses the human resources and scientific expertise required to become a major pharmaceutical manufacturing hub but stressed that stronger cooperation among government institutions, industry players and professional bodies was necessary to achieve that ambition.
He called for a collective approach to developing the sector, noting that professional excellence must translate into practical contributions to national healthcare and economic growth.
Meanwhile, the recipient of the Lifetime Achievement Award, Pharm. Stella Okoli, encouraged pharmacists to remain committed to strengthening Nigeria’s pharmaceutical industry and urged younger professionals to acquire practical experience in medicine manufacturing.
She also reflected on previous government policies that supported local pharmaceutical production, stressing the importance of sustained policy commitment to enable domestic manufacturers to expand their operations.
Former President of the Pharmaceutical Society of Nigeria and Vice President of the Academy, Pharm. Ahmed Yakasai, also called for greater professional integrity, improved competence and stronger efforts to combat fake and substandard medicines.
He emphasised the importance of pharmacovigilance and collaboration across the pharmaceutical supply chain in protecting public health and maintaining confidence in medicines distributed within the country.
Nigeria’s Pharmaceutical Independence Challenge
Nigeria’s ambition to produce 70 per cent of its medicines locally comes amid longstanding concerns about its dependence on imported pharmaceutical products and raw materials.
Although the country has established pharmaceutical manufacturing companies, local producers continue to face challenges, including high production costs, infrastructure deficits, limited access to financing, dependence on imported active pharmaceutical ingredients and inconsistent policy implementation.
Achieving the 2030 target will therefore require more than policy declarations. Sustained investment in manufacturing infrastructure, research and development, technology transfer, reliable energy supply and effective regulatory oversight will be critical.
For Nigeria and other African countries seeking greater control over their healthcare systems, strengthening domestic pharmaceutical production represents an important step towards reducing external vulnerabilities, creating industrial opportunities and improving access to quality medicines.
The renewed call by WHO and the Nigerian Academy of Pharmacy places responsibility on government, manufacturers, researchers and healthcare professionals to translate the country’s medicine sovereignty ambitions into measurable progress.

